健帆生物：10月13日召开董事会会议

Group 1 - The core point of the article is that Jianfan Biological (SZ 300529) held its 33rd meeting of the fifth board of directors on October 13, 2025, where it reviewed the proposal regarding not adjusting the conversion price of Jianfan convertible bonds [1] - For the year 2024, Jianfan Biological's revenue composition is as follows: 99.71% from the medical device manufacturing industry and 0.29% from other sources [1] - As of the time of reporting, Jianfan Biological has a market capitalization of 17.3 billion yuan [1]